NPPB and myocardial infarction: The primary endpoint is myocardial infarct size after 4 months; secondary endpoints include the effects of Na2S2O3 on peak CK-MB (creatine kinase muscle brain type, as an early measure of MI) during admission and left ventricular ejection fraction and NT-proBNP (N terminal pro brain natriuretic peptide, as a measure of heart insufficiency) levels at 4 months follow-up [75].